Clay Siegall is nature’s answer to rare diseases and ailments. The CEO of Seattle Genetics heads one of the companies that can produce the cure of modern incurable maladies.
Clay Siegall’s blog
Clay Siegall addresses numerous pressing issues in his blog. The blog is a reflection of what is happening in the modern Biotech world and the whole universe as a whole.Some of these matters show that although science is developing, some of the progress leaves a lot to be desired. He doesn’t deserve the only critic the gray areas of genetics in his blog; he also informs his readers about different strides that scientists are making.This blog is a must read for not only the genetics enthusiasts but also the scientists.
About Clay Siegall
Clay B. Siegall is the current president of the Board and President of Seattle Genetics. He also assisted in starting the company in 1998. Dr. Siegell has managed to propel Seattle Genetics to a successful company, and he has been able to raise several billion for the company’s capital in fund raising activities.
The scientist worked for Bristol-Myers Squibb Pharmaceutical Research Institute before joining Seattle Genetics.
Other institutions that he has worked for include Ultragenyx Pharmaceutical where he is the present Director of the board of directors. He is also the current Director, Board of Directors of Mirna Therapeutics, Inc, and Alder Biopharmaceuticals.Clay has been honored severally for his role in Biotechnology, some of these awards include; University of Maryland Alumnus of the Year in Computer, Math and Natural Sciences in 2013 and Ernst & Young Pacific Northwest Entrepreneur of the Year in 2012. He has 15 patents and has written around 70 publications.
About Seattle Genetics
Seattle Genetics was started in 1998 to develop drug practices, perform scientific innovation and do thorough research.The company has succeeded in making strides in the manufacture of antibody-drug conjugates (ADC). The company is now set on developing a new line of ADCs for combating cancer.Seattle Genetics has managed to partner with some of the biggest names in the pharmaceutical world to produce and develop ADC’s.
Clay Siegall is the chairman of the board, president, and CEO of Seattle Genetics. Siegall is a trained scientist. His research has heavily focused on targeted cancer therapies. In 1998, Siegall founded Seattle Genetics. The company is regarded as a market leader in the development of cancer drugs, research, and scientific innovation. Siegall has always been passionate about assisting patients. Through his transformative leadership, Siegall has led Seattle Genetics to its current top position in terms of developing antibody-drug conjugates for cancer treatment.
Additionally, under Clay Siegall’s guidance, the company has entered into numerous strategic partnerships for its antibody-drug conjugate technology. Seattle has strategic licenses with AbbVie, Pfizer, Genentech, and GlaxoSmithKline. These partnerships have generated over $300 million. Seattle Genetics has inspired the development of internal and collaborator programs. Currently, over 20 ADCs are in clinical development. They are using the company’s technology.
In addition, Clay Siegall has secured over $650 million in capital. He has managed to raise huge capital through public and private financing. This includes Seattle Genetics’ initial public offering, which was effected in 2001.
Before establishing Seattle Genetics, Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute. Between 1991 and 1997, he was a senior employee at the National Cancer Institute. In 1988, Siegall joined the National Institute of Health where he rendered his services until 1991.
Currently, Siegall serves on the board of directors of Washington Biotechnology and Biomedical Association as well as Alder BioPharmaceuticals. In addition, he is a member of the Fred Hutchinson Cancer Research Business Alliance’s board of governors. In 2013, Siegall was appointed to Mirna Therapeutics’ board of directors. The biotechnology firm focuses on enhancing the development and commercialization of microRNA. The company was excited to appoint Siegall given his wide-ranging experience in the pharmaceutical industry.
During CHI’s 5th Annual Antibody-Drug Conjugates Conference (PEGS Summit), which was held in Boston, Clay Siegall was given the opportunity to make a keynote presentation. He shared his experiences and perspectives on the future of Seattle Genetics. Siegall noted that the company was proud because its product, ADCETRIS, had treated over 15,000 lymphoma patients across the globe. Clay discussed at length about the prospects and trends of the ADCs field. He concluded by reiterating the steps that he would take to overcome the emerging challenges.